- Oops!Something went wrong.Please try again later.
The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues.
The results were highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress.
IMC‑1 exhibited an encouraging safety profile, as adverse events occurred at a lower rate and were less severe in the IMC‑1 treatment group compared with placebo.
The discontinuation rate was nearly 3‑fold higher in patients receiving placebo than the IMC‑1 group, suggesting that treatment with IMC‑1 was unusually well‑tolerated.
Significant reductions in pain, fatigue, and other vital symptoms were observed.
Price Action: VIRI shares are up 12.1% at $6.30 during the premarket session on the last check Wednesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.